AU6230098A - Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors - Google Patents

Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors

Info

Publication number: AU6230098A
Authority: AU; Australia
Prior art keywords: preparing; same; phosphodiesterase inhibitors; isoquinolinone derivatives; isoquinolinone
Prior art date: 1997-02-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mitsubishi Tanabe Pharma Corp

Original Assignee

Tanabe Seiyaku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-23Application filed by Tanabe Seiyaku Co LtdfiledCriticalTanabe Seiyaku Co Ltd

1998-09-18Publication of AU6230098ApublicationCriticalpatent/AU6230098A/en

StatusAbandonedlegal-statusCriticalCurrent

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU62300/98A1997-02-271998-02-23Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitorsAbandonedAU6230098A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP9-44408		1997-02-27
JP4440897		1997-02-27
PCT/JP1998/000715WO1998038168A1 (en)	1997-02-27	1998-02-23	Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number	Publication Date
AU6230098Atrue AU6230098A (en)	1998-09-18

Family

ID=12690695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU62300/98AAbandonedAU6230098A (en)	1997-02-27	1998-02-23	Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors

Country Status (2)

Country	Link
AU (1)	AU6230098A (en)
WO (1)	WO1998038168A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6410584B1 (en)	1998-01-14	2002-06-25	Cell Pathways, Inc.	Method for inhibiting neoplastic cells with indole derivatives
AU5305299A (en)*	1998-08-26	2000-03-21	Tanabe Seiyaku Co., Ltd.	Naphthyridine derivatives and process for the preparation thereof
US6200771B1 (en)	1998-10-15	2001-03-13	Cell Pathways, Inc.	Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en)*	1998-11-19	2000-10-17	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en)	1998-11-20	2001-02-13	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en)	1998-11-23	2002-04-09	Cell Pathways, Inc.	Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en)*	1998-11-24	2000-06-20	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en)*	1998-11-24	2000-03-07	Cell Pathways, Inc.	Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en)	1998-11-24	2002-11-26	Cell Pathways Inc	Method of inhibiting neoplastic cells with isoquinoline derivatives
US6020379A (en)*	1999-02-19	2000-02-01	Cell Pathways, Inc.	Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
YU54202A (en)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
HN2001000008A (en)	2000-01-21	2003-12-11	Inc Agouron Pharmaceuticals	AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
CA2398446A1 (en)	2000-04-18	2001-10-25	Agouron Pharmaceuticals, Inc.	Pyrazoles for inhibiting protein kinases
EP1316316B1 (en)	2000-09-06	2012-04-04	Mitsubishi Tanabe Pharma Corporation	Preparations for oral administration
US6821978B2 (en)	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
EP1322619B1 (en)*	2000-09-20	2008-01-23	Merck & Co., Inc.	Isoquinolinone potassium channel inhibitors
PL364221A1 (en)*	2001-02-02	2004-12-13	Takeda Chemical Industries, Ltd.	Fused heterocyclic compounds
MXPA03007283A (en)	2001-02-15	2003-12-04	Tanabe Seiyaku Co	Tablets quickly disintegrated in oral cavity.
WO2003042216A1 (en)	2001-11-09	2003-05-22	Schering Corporation	Polycyclic guanine derivative phosphodiesterase v inhibitors
EP1484320A1 (en)	2002-02-13	2004-12-08	Takeda Chemical Industries, Ltd.	Jnk inhibitor
US7276529B2 (en)	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en)	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AU2003289305A1 (en)*	2002-12-11	2004-06-30	Nissan Chemical Industries, Ltd.	Novel diaminobenzene derivative, polyimide precursor and polyimide obtained therefrom, and aligning agent for liquid crystal
JP4977837B2 (en)	2003-09-10	2012-07-18	アイカジェン，インコーポレイテッド	Fused ring heterocycles as potassium channel modulators
AU2004276267B2 (en)*	2003-09-23	2010-08-19	Merck Sharp & Dohme Corp.	Isoquinolinone potassium channel inhibitors
DE602005017135D1 (en)	2004-03-05	2009-11-26	Nycomed Gmbh	NEW USE OF PDE5 INHIBITORS
JP5070052B2 (en)	2004-08-17	2012-11-07	ザ・ジョンズ・ホプキンス・ユニバーシティ	PDE5 inhibitor composition and method for treating heart disease
TWI417095B (en)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
US9623021B2 (en)	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
US20130116277A1 (en)*	2007-01-22	2013-05-09	James T. Dalton	Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
US9604931B2 (en)	2007-01-22	2017-03-28	Gtx, Inc.	Nuclear receptor binding agents
EP2106212B1 (en)*	2007-01-22	2014-04-02	GTX, Inc.	Nuclear receptor binding agents
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP5239231B2 (en)*	2007-07-06	2013-07-17	株式会社リコー	Diamine compound, polyamic acid and soluble polyimide, and wettability changing film and electrode obtained therefrom
WO2009033704A1 (en)	2007-09-14	2009-03-19	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
WO2009124119A2 (en)*	2008-04-01	2009-10-08	The Trustes of Columbia University in the City of New York	Phosphodiesterase inhibitors and uses thereof
CA2735764C (en)	2008-09-02	2016-06-14	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en)	2008-11-28	2010-06-03	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
GB2466073A (en)	2008-12-12	2010-06-16	Univ Manchester	Tissue repair scaffold
JP2012513464A (en)	2008-12-23	2012-06-14	ザトラスティーズオブコロンビアユニヴァーシティインザシティオブニューヨーク	Phosphodiesterase inhibitors and uses thereof
EA020671B1 (en)	2009-05-12	2014-12-30	Янссен Фармасьютикалз, Инк.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS
SG176021A1 (en)	2009-05-12	2011-12-29	Janssen Pharmaceuticals Inc	1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US9271967B2 (en)	2010-11-08	2016-03-01	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2643320B1 (en)	2010-11-08	2015-03-04	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2552879T3 (en)	2010-11-08	2015-12-02	Janssen Pharmaceuticals, Inc.	1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2938343B1 (en)	2012-12-21	2018-09-12	Mayo Foundation For Medical Education And Research	Methods and materials for treating calcific aortic valve stenosis
JP6488239B2 (en)	2013-01-18	2019-03-20	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Phthalazinone and isoquinolinone as ROCK inhibitors
US8937178B2 (en)	2013-03-13	2015-01-20	Flatley Discovery Lab	Phthalazinone compounds and methods for the treatment of cystic fibrosis
JO3368B1 (en)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
JO3367B1 (en)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AU2015208233B2 (en)	2014-01-21	2019-08-29	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
LT3431106T (en)	2014-01-21	2021-02-10	Janssen Pharmaceutica Nv	Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
EP3157520B1 (en)	2014-06-23	2019-09-04	Celgene Corporation	Apremilast for the treatment of a liver disease or a liver function abnormality
US9902702B2 (en)	2014-07-15	2018-02-27	Bristol-Myers Squibb Company	Spirocycloheptanes as inhibitors of rock
MX2021012409A (en)	2019-04-10	2021-11-12	Mayo Found Medical Education & Res	Methods and materials for gender-dependent treatment of cardiovascular dysfunction.
CN116693456A (en)*	2022-02-28	2023-09-05	复旦大学	Isoquinolinone compound and its preparation method and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2098980B (en)*	1981-03-28	1985-05-15	Taiho Pharmaceutical Co Ltd	1(2h)-isoquinolone compounds and acid addition salts thereof
GB9027055D0 (en)*	1990-12-13	1991-02-06	Sandoz Ltd	Organic compounds
ATE161530T1 (en)*	1992-09-04	1998-01-15	Takeda Chemical Industries Ltd	CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE
EP0634402A1 (en)*	1993-07-14	1995-01-18	Takeda Chemical Industries, Ltd.	Isochinolinone derivatives, their production and use

1998
- 1998-02-23AUAU62300/98Apatent/AU6230098A/ennot_activeAbandoned
- 1998-02-23WOPCT/JP1998/000715patent/WO1998038168A1/ennot_activeCeased

Also Published As

Publication number	Publication date
WO1998038168A1 (en)	1998-09-03

Publication	Publication Date	Title
AU6230098A (en)	1998-09-18	Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
AU3734799A (en)	1999-12-06	5-demethoxyfumagillol derivatives and processes for preparing the same
AU5194999A (en)	2000-02-28	Benzothiepin derivatives, process for the preparation of the same and uses thereof
GB9823873D0 (en)	1998-12-30	2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
HUP0203425A3 (en)	2003-07-28	Quinazoline derivatives, process for their preparation and their use
HUP0001115A3 (en)	2001-06-28	Heterocyclylmethyl-substituted pyrazol derivatives, process for their preparation and pharmaceuticals containing the same
AU4308397A (en)	1998-04-02	Substituted 2-pyrimidineamines, their preparation and their use as proteine kinase inhibitors
HUP0103111A3 (en)	2003-01-28	Epothilone derivatives, process for their preparation and their use
ZA200006577B (en)	2002-04-24	Phthalazine derivatives as phosphodiesterase 4 inhibitors.
GB9823871D0 (en)	1998-12-23	2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
PL351148A1 (en)	2003-03-24	5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
HUP0004747A3 (en)	2002-12-28	4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation
AU2002221753A1 (en)	2002-07-11	Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
AU1596097A (en)	1997-08-22	Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
HUP9903492A3 (en)	2000-08-28	Quinoline derivatives as type iv phosphodiesterase inhibitors, process for their preparation, pharmaceutical compositions containing the same and their use
AU5652698A (en)	1998-06-03	(2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
AU2701697A (en)	1997-12-05	Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
AU1628397A (en)	1997-09-25	Fluoroalkyl- and fluoroalkoxy-substituted heterocyclic bradykinin antagonists, process for their preparation, and their use
AU4501199A (en)	1999-12-20	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU7446900A (en)	2001-04-30	Thioalkylamine derivatives and process for the preparation thereof
ZA976329B (en)	1998-01-19	Substituted pyrazolylpyrazole derivatives, process for their preparation, and their use as herbicides.
GR3035834T3 (en)	2001-08-31	Benzoxazindione derivatives, process for their preparation and their use
AU3708397A (en)	1998-02-25	Sulfonic ester derivatives, process for preparing the same, and use thereof
AU3218195A (en)	1996-03-14	Alpha-d-pentofuranoside derivatives, process for preparing the same and their use
AU4263799A (en)	1999-12-06	Pyridyl-pyrazole derivatives, process for their preparation, and their use as herbicides

Movatterモバイル変換

AU6230098A - Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=12690695

Family Applications (1)

Country Status (2)

Families Citing this family (60)

Family Cites Families (4)

Also Published As

Similar Documents